Liliana Š.
- Country
- Czechia
- Department
- Rheumatology
Research Overview
- An Open-Label Extension Study to Evaluate Long Term Safety and Efficacy of Tildrakizumab in Patients with Psoriatic Arthritis.
- A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis
- Efficacy and Safety of Tildrakizumab in Anti-TNF Naive Patients with Active Psoriatic Arthritis: A Phase III Randomized, Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 130 of 168 partner sites.
Specializations
Inflammatory Arthritis
This investigator specializes in the treatment and research of psoriatic arthritis (PsA), with particular emphasis on developing innovative therapeutic approaches for both treatment-experienced and treatment-naïve patients.
- Biologic DMARD therapies
- Anti-TNF treatment outcomes
- Novel therapeutic agents
The research focus includes evaluating treatment responses in different patient populations affected by active PsA.
Treatment Innovation
Expertise in investigating novel biological treatments, including tildrakizumab and sonelokimab, for autoimmune arthritic conditions.
- Long-term safety assessments
- Treatment efficacy evaluation
- Therapeutic response monitoring
The investigator focuses on establishing effective treatment protocols through systematic clinical evaluation.
Clinical Assessment
Specialized in utilizing standardized assessment tools such as the American College of Rheumatology response criteria to evaluate therapeutic effectiveness.
- Response measurement protocols
- Treatment outcome analysis
- Patient response monitoring
Expertise includes comprehensive evaluation of treatment outcomes in inflammatory arthritis conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.